慢性心力衰竭药物治疗进展  

Advance of drug therapy for chronic heart failure

作　　者：张骞[1] 刘小慧[1] 董建增[1] 

机构地区：[1]首都医科大学附属北京安贞医院心内科,北京100029

出　　处：《中国实用内科杂志》2016年第4期272-276,共5页Chinese Journal of Practical Internal Medicine

摘　　要：心力衰竭是指心脏结构或功能异常导致-心室充盈或射血能力受损的一组临床综合征，是各种心脏疾病发展的终末阶段。流行病学资料表明发达国家成人心力衰竭的患病率为1％～2％，并且随着年龄的增加其患病率显著增高。慢性心力衰竭的药物治疗从最初的强心、利尿、扩血管等改善短期血流动力学，转变为抑制神经内分泌系统以延缓心室重构、提高生活质量、降低住院率和病死率的长期策略。慢性心力衰竭依据左室射血分数可以分为射血分数降低的心力衰竭和射血分数保留的心力衰竭，目前尚无明确的治疗手段能有效的降低射血分数保留心力衰竭的发生率与病死率，因而文章将主要对射血分数降低的慢性心力衰竭的药物治疗进行概述。Heart failure （HF） is a complex syndrome resulting from a structural or functional abnomality that impairs the ability of ventricular filling or cardiac ejection. It is the terminal phase of a variety of cardiovascular diseases, and impacts an estimated 1-2% adults in developed countriess with an increasing prevalence in the elderly. Key clinical trials have established an evidence-based foundation of heart failure with reduced ejection fraction （HFrEF） treatment. In current clinical practice, neurohormonal blockers has been used to reverse ventricular remodelling, improve quality of life, decrease HF-related rehospitalization and mortality, and have been leading to marked reductions in morbidity and mortality in HFrEF. Clinical application will be better defined in the coming years. This review will focus on the drug therapy in HFrEF.

关 键 词：心力衰竭 射血分数 心室重构 

分 类 号：R541.61[医药卫生—心血管疾病]